Is cessation of clopidogrel therapy associated with rebound of platelet activity in stable vascular disease patients? - a randomised double-blind placebo-controlled trial

Grampian Health Board and University of Aberdeen (UK)0 个研究点目标入组 156 人开始时间: 2009年4月21日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Both males and females, age 30-80 years
•2. Evidence of chronic atherosclerotic disease - stable coronary heart disease or peripheral arterial disease
•3. Already receiving standard secondary prevention therapy for cardiovascular disease, including aspirin therapy and a statin
•4. Able to give informed consent

•1. Known allergy to clopidogrel
•2. Contraindications to clopidogrel as listed in the Summary of Product
•3. Characteristics for clopidogrel (i.e Hypersensitivity to the active substance or to any of the excipients of the medicinal product, severe liver impairment, active pathological bleeding such as peptic ulcer or intracranial haemorrhage, breast feeding)
•4. History of thrombocytopenia, neutropenia or haematological malignancy
•5. Bleeding diathesis
•6. Abnormal renal or hepatic function
•7. Transfusion of whole blood cells within 14 days prior to randomisation
•8. Known or suspected drug or alcohol abuse
•9. Clinical symptoms of heart failure
•10. Women of child-bearing potential
•11. Taking anticoagulant or antiplatelet drugs other than aspirin
•12. Participation in another clinical trial of a medicinal product (CTIMP) within preceding 3 months

发起方

Grampian Health Board and University of Aberdeen (UK)